Acadia Pharmaceuticals (ACAD) Accounts Payables (2010 - 2026)

Acadia Pharmaceuticals' Accounts Payables history runs 17 years deep, the most recent figure standing at $12.2 million for Q1 2026.

• On a quarterly basis, Accounts Payables fell 32.32% year-over-year to $12.2 million in Q1 2026; TTM through Mar 2026 was $12.2 million, a 32.32% decrease from a year earlier, with the FY2025 full-year figure at $10.9 million, down 32.66% from the prior year.
• Accounts Payables climbed to $12.2 million in Q1 2026 per ACAD's latest filing, from $10.9 million in the prior quarter.
• Across five years, Accounts Payables topped out at $21.7 million in Q3 2025 and bottomed at $10.0 million in Q3 2022.
• The 5-year median for Accounts Payables is $17.4 million (2023), against an average of $15.8 million.
• Across the five-year window, Accounts Payables soared 85.37% in 2022 and plunged 32.66% in 2025, its largest moves.
• Year by year, Accounts Payables stood at $12.7 million in 2022, then soared by 37.64% to $17.5 million in 2023, then decreased by 7.7% to $16.2 million in 2024, then sank by 32.66% to $10.9 million in 2025, then grew by 12.32% to $12.2 million in 2026.
• Per Business Quant, the three latest ACAD Accounts Payables figures stand at $12.2 million (Q1 2026), $10.9 million (Q4 2025), and $21.7 million (Q3 2025).